Drugs moving into the clinic: 7
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
A list of drugs moving into clinical trials Sponsor Name Indication Mechanism Symphogen & Biovitrum Sym001 (Anti-RhD) Idiopathic Thrombo-cytopenic Purpura (ITP) treatment and Hemolytic Disease of the Newborn (HDN) (prevention) Recombinant, polyclonal antibody product candidate, comprised of 25 different anti-Rhesus D antibodies Artielle Immuno- Therapeutics RTL1000 Multiple sclerosis Antigenic peptide - binds to T cells, preventing the release of the inflammatory cytokines and causing the release of anti-inflammatory cytokines, thus protecting myelin sheath around nerves in brain and spinal cord Diffusion Pharmaceuticals trans sodium crocetinate (TSC) Numerous hypoxia related indications e.g. stroke, trauma, cardiovascular disease, respiratory disorders. Enhance the diffusion of oxygen into tissue Exelixis XL147 Oncology Small molecule inhibitor of phospho-inositide-3 kinase or PI3K Potentia Pharmaceuticals POT-4 age-related macular degeneration (AMD) Complement component C3 inhibitor - shuts down the complement activation system that could lead to local inflammation, tissue damage and upregulation of angiogenic factors such as VEGF Pain Therapeutics undisclosed Oncology - metastatic melanoma Evaluate the pharmaco-kinetics of a proprietary radio-labelled monoclonal antibody Evotec EVT 302 Smoking cessation Reversible inhibitor of monoamine oxidase B enzyme (MAO-B) Biotron BIT225 HIV Blocks the ion channel activity of 'viroporins', inhibiting viral budding and replication. Specifically, Vpu, which promotes CD4 breakdown to enhance release of virus particles.